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Abstract
Background: The soluble factors secreted by mesenchymal stem cells are thought to either support or inhibit
tumor growth. Herein, we investigated whether the human lung-derived mesenchymal stem cell-conditioned
medium (hlMSC-CM) exerts antitumor activity in malignant pleural mesothelioma cell lines H28, H2052 and Meso4.
Methods: hlMSC-CM was collected from the human lung-derived mesenchymal stem cells. Inhibition of tumor cell
growth was based on the reduction of cell viability and inhibition of cell proliferation using the XTT and BrdU
assays, respectively. Elimination of tumor spheroids was assessed by the anchorage-independent sphere formation
assay. The cytokine profile of hlMSC-CM was determined by a chemiluminescence-based cytokine array.
Results: Our data showed that hlMSC-CM contains a broad range of soluble factors which include: cytokines,
chemokines, hormones, growth and angiogenic factors, matrix metalloproteinases, metalloproteinase inhibitors and
cell–cell mediator proteins. The 48- and 72-hour hlMSC-CM treatments of H28, H2052 and Meso4 cell lines elicited
significant decreases in cell viability and inhibited cell proliferation. The 72-hour hlMSC-CM incubation of H28 cells
completely eliminated the drug-resistant sphere-forming cells, which is more potent than twice the half maximal
inhibitory concentration of cisplatin.
Conclusions: Our findings indicate that the cell-free hlMSC-CM confers in vitro antitumor activities via soluble
factors in the tested mesothelioma cells and, hence, may serve as a therapeutic tool to augment the current
treatment strategies in malignant pleural mesothelioma.
Keywords: Malignant pleural mesothelioma, Human lung mesenchymal stem cell-conditioned medium, Soluble
factors, Sphere-forming cells, Cisplatin
Introduction
In contrast to the early paradigm of cell replacement
and differentiation of mesenchymal stem cells (MSCs) as
a therapeutic mechanism, reports are accumulating that
cell secretions are responsible for their beneficial effects
[1]. MSCs are known to secrete a wide range of bioactive
molecules such as growth factors, cytokines and chemo-
kines that regulate their biology in an autocrine or
paracrine manner in accordance with the environmental
niche [2]. It has been recognized that MSC activities are
mediated by secreted biomolecules, highlighting the
importance of using MSC-derived conditioned media
(MSC-CM) in regenerative medicine as well as in cancer
therapy. Clinically, the use of cell-free MSC-CM may
represent a better therapeutic tool compared with stem
cell-based therapy as the former is easier to prepare,
maintain, and transport to appropriate sites, and may
also have less complications related to issues on cell
transplants [3].
When MSCs arrive at a tumor niche, they produce a
variety of soluble factors that either positively or nega-
tively influence tumor growth [4]. Several reports have
accounted for the antitumorigenic capacity of MSCs.
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Khakoo et al. [5] have demonstrated that intravenously
injected human MSCs (hMSCs) in a mouse model of
sarcoma could potently inhibit tumor growth. Cell
lysates or supernatants of Wharton’s jelly-derived MSCs
have manifested a capacity to inhibit cell growth of
breast cancer, ovarian tumor and osteosarcoma cell lines,
indicating tumor inhibitory properties [6]. Although
hMSCs have been demonstrated to suppress prolifera-
tion and induce apoptosis of SKMES-1 and A549 lung
adenocarcinoma cells via some soluble factors [7], no
current knowledge of hMSC-CM actions on malignant
pleural mesothelioma (MPM) is known.
MPM is a highly aggressive, chemoresistant lung
cancer with a median survival of <1 year after diagnosis
[8, 9]. Thus, new therapeutic strategies are imperative to
improve patient survival. Given that soluble factors
secreted by MSCs are supposed to mediate beneficial
effects, we investigated whether the cell-free hlMSC-CM
exerts an antitumor capacity in three MPM cell lines.
Materials and methods
Cell culture
The H28 and H2052 mesothelioma cell lines (LCD
Promochem, France) were cultured in RPMI 1640 (PAA,
Austria) containing 10 % fetal bovine serum (FBS; PAA,
Austria) and 1 % penicillin/streptomycin (Invitrogen,
Switzerland). ACC-Meso-4 cell line was obtained from
Riken Cell Bank, Resource No: RBRC-RCB2293 (Ibaraki,
Japan) and cultured using the above-mentioned culture
medium. Cells were maintained at 37 °C, 95 % humidity
and 5 % CO2.
Isolation and characterization of hlMSCs
We have previously identified human lung parenchyma
mesenchymal stromal cells, which are referred as human
lung-derived mesenchymal stem cells (hlMSCs) in this
study. hlMSCs were isolated by using our established
protocol as reported in our previous work [10], which
includes immunophenotyping and in vitro mesenchymal
trilineage differentiation into chondrocytes, adipocytes
and osteocytes (see Additional file 1).
Collection of hlMSC-CM
Conditioned medium (CM) was collected from hlMSCs
at passage 3. Cells were cultured at a density of 5 × 104
in 10 cm cell culture dish containing MCDB 201 supple-
mented with ITS, 1 % antibiotic/antimytotic reagent
(Hyclone), 1 % FBS and 20 ng/μl endothelial growth fac-
tor at 37 °C in a humid atmosphere with 5 % CO2. Upon
reaching 70–80 % confluency, cells were washed once with
phosphate-buffered saline (PBS) and then re-incubated
with a serum-free MCDB 201 medium for 24 hours. The
CM (supernatant) was then collected and centrifuged at
1200 × g for 10 minutes to remove cell components and
was sterilized by passing through a 0.2-μm cell filter
(BD Biosciences, Switzerland). Aliquots were sub-
jected to cytokine array analysis or frozen at −80 °C
for future applications. hlMSC-CM was used as it
was, without dilution or addition of serum in all of
the experiments in this project.
Cell proliferation and cell viability assays
The XTT and BrdU assays were performed to assess the
effect of hlMSC-CM on cell viability and cell prolifera-
tion, respectively (see Additional file 2).
Cytokine array assay
The cytokine profile of hlMSC-CM was determined
using the Human Angiogenesis Antibody Array (see
Additional file 3).
Sphere formation
The sphere formation assay used to evaluate the forma-
tion of nonadherent multicellular spheroids is described
in Additional file 4.
Drug treatment
For drug treatment, cisplatin (diamminedichloroplatinum
(II); Bristol Myers Squibb, Switzerland) was used. Cells
were seeded at a density of 5 × 104 cells/well in six-well
culture dishes and incubated for 24 hours prior to
48- and 72-hour treatments with the half maximal in-
hibitory concentration (IC50) or twice the IC50 of cis-
platin (twice the IC50 means 2× the concentration of
the IC50 value). The specified concentration corre-
sponds to the previously determined IC50 value of the
three MPM cell lines: H28 (15 μM), H2052 (13 μM),
and Meso4 (12 μM) [11]. Following the cisplatin treat-
ments at 37 °C, cells were washed with PBS, trypsi-
nized, and single-cell suspension was prepared for
sphere formation assay.
Statistical analysis
Data are reported as means ± standard deviations. For
analysis of differences in multiple groups, one-way
analysis of variance and Bonferroni’s post-hoc test were
performed using Prism 6.0 (GraphPad Software, USA).
A p value <0.05 was considered significant.
Results
hlMSC-CM contains soluble factors
We have previously identified hlMSCs exhibiting plastic
adherence, the immunophenotype and trilineage differ-
entiation capacity consistent with the established
features of MSCs [10, 12, 13]. We initially investigated
whether our hlMSC-CM contains soluble factors. We
therefore collected the CM of the hlMSCs grown for
24 hours in the absence of FBS and analyzed it using the
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cytokine array. hlMSC-CM contained a broad range of
soluble factors which included: cytokines, chemokines,
hormones, growth factors, neurotrophic factors, endo-
crine and angiogenic factors, matrix metalloproteinases
(MMPs), metalloproteinase inhibitors (TIMPs) and cell–
cell mediator proteins (Fig. 1).
hlMSC-CM inhibits cell proliferation and reduces cell
viability in three MPM cells lines
We studied the effect of hlMSC-CM on the prolifera-
tive activity of H28, H2052 and Meso4 using the
BrdU assay. The 48- and 72-hour treatments with
hlMSC-CM elicited significant reductions in cell pro-
liferation of H28 (48 hours –74 %; 72 hours –76 %),
H2052 (48 hours –62 %; 72 hours –64 %) and Meso4
(48 hours –35 %; 72 hours –55 %) relative to the
nontreated cells (Fig. 2a–c). We also investigated the
effect of hlMSC-CM on cell viability after the treat-
ment periods of 48 and 72 hours using the XTT
assay. hlMSC-CM evoked significant reductions in cell
viability in all tested cell lines: H28 (48 hours –69 %;
72 hours –81 %), H2052 (48 hours –25 %; 72 hours –
25.3 %), Meso4 (48 hours –26.3 %; 72 hours –31 %) com-
pared with the nontreated cells (Fig. 2d–f).
hlMSC-CM eliminates sphere-forming phenotype in
H28 cells
In our previous work, we found cisplatin-resistant
tumor spheres in H28, H2052 and Meso4 indicating
the presence of putative cancer stem cells (CSCs),
which may, in part, be responsible for drug resistance
[11]. Hence, we investigated the ability of hlMSC-CM
to eliminate these cells, and also compared its efficacy
with cisplatin, a standard chemotherapy in the treat-
ment of MPM [8, 9]. hlMSC-CM significantly reduced
the sphere-forming efficiency by 70 % in H28 cells
after 48 hours and, unexpectedly, fully eliminated
them after the 72-hour treatment (Fig. 3a). These
effects were not observed in H2052 and Meso4 cells
(Fig. 3b and c). Representative images of the non-
treated and hlMSC-CM-treated MPM cells are shown
in Fig. 3d–f.
We then compared the inhibitory effect of hlMSC-
CM on the growth of tumor spheres with that of
IC50 and twice the IC50 of cisplatin in H28 cells. The
48-hour hlMSC-CM treatment significantly reduced
the sphere-forming efficiency by 74 %, whereas the
72-hour incubation completely eliminated the tumor
spheres (Fig. 4a). Using the IC50 of cisplatin, we ob-
tained significant 50 % reductions in sphere efficiency
after the 48- and 72-hour treatments (Fig. 4b), and
significant decreases of 68 and 73 % after analogous
incubation periods using twice the IC50 of cisplatin
(Fig. 4c). Our results showed that hlMSC-CM is
capable of fully eliminating the sphere-forming
phenotype in H28 cells, and that this effect has a
higher efficacy compared with twice the IC50 of cis-
platin. Representative images of the nontreated and
hlMSC-CM-treated H28 cells are shown in Fig. 4d–f.
Discussion
One beneficial effect of MSCs is their inherent antitu-
mor capacity—a current topic of investigation because
of its future role in cancer therapy. Here, we report
that hlMSC-CM contains a broad range of soluble
factors, which conferred inhibition of cell proliferation
and a decrease in cell viability in three MPM cell
lines. Importantly, hlMSC-CM completely eliminated
the cisplatin-resistant, sphere-forming cells.
We found a huge panel of cytokines, chemokines,
growth, neurotrophic, endocrine and angiogenic
factors, MMPs, TIMPs and cell–cell mediator proteins
in our hlMSC-CM that elicited suppression of cell
growth and reduced cell viability in the tested meso-
thelioma cells. These data substantiate the current
paradigm that MSC-dependent beneficial effects are
mediated primarily by secreted factors [1]. Evidences
for the soluble factor-mediated antitumor capacity of
hMSC-CM have been reported such as the reduction
of SK-MES-1 and A549 lung cancer cell proliferation
by a downregulation of vascular endothelial growth
factor (VEGF) expression and by an increased apop-
tosis ratio compared with the non-hMSC-CM-treated
cells [7]. The in vitro treatment of ovarian cancer
cells with heat shocked adipose stem cell-derived CM
and amniotic-derived stem cells have resulted in
decreased tumor cell viability compared with controls
by inducing greater nuclear condensation and growth
cycle arrest of tumor cells. Cytokine array of the CM
demonstrated that the observed antitumor effect was
mediated by angiogenin, IGF-binding protein 4, NT-3
and chemokine ligand 18 [14]. In a coculture study of
lung adenocarcinoma (LAC) cell lines and MSCs or
MSC-CM, Wang et al. [15] have shown evidence that
oncostatin M, a differentiation-promoting cytokine,
mediated the MSC-dependent inhibition of tumori-
genicity and activation of mesenchymal epithelial
transition in LAC cells. Extracellular matrix compo-
nents produced by human umbilical cord blood MSCs
have also contributed to the growth arrest of meta-
static cancer cells by an upregulation of tumor sup-
pressor phosphatase and tensin homolog (PTEN) in
the tumor cells [16]. The data in our cytokine array
include factors that are likely involved in conferring
antitumorigenic effects of MSCs such as angiogenin,
VEGF, transforming growth factor-beta (TGF-b) and hep-
atocyte growth factor (HGF) [14, 17]. They also showed
increased levels of biomolecules that have been linked to
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Fig. 1 hlMSC-CM contains a broad range of soluble factors. The CM (supernatant) of hlMSCs grown for 24 hours in a culture medium without
FBS was collected and subjected to a cytokine array assay as described in the Materials and methods. Results are representative of one of the
three independent experiments
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diverse roles in the malignant setting, which include
IGFBP-1, IGFBP-2, CCL2, Pentraxin, SerpinE1, SerpinE2,
TIMP-1 and uPA [18–23]. Further investigation is ne-
cessary to identify the specific factors that are impli-
cated in the observed antitumorigenic property of
hlMSC-CM in the tested mesothelioma cells.
MSCs have diverse effects on tumor growth. In contrast
to the reported tumor-promoting capacity of MSCs, our
findings showed a tumor-inhibiting effect of hlMSC-CM
in the tested MPM cell lines. Tumor-promoting activity is
exerted either by paracrine secretion of growth factors
and antiapoptotic factors, or by differentiating into
tumor-associated fibroblasts, which can enhance
tumor growth, metastasis formation and therapy re-
sistance [4]. Adversely, MSCs and/or MSC-derived
CM also confer antitumorigenic responses as have
Fig. 2 The inhibitory effect of hlMSC-CM on cell proliferation and reduction of cell viability in the three MPM cells lines. Significant inhibitions on
cell proliferation of hlMSC-CM-treated H28 (a), H2052 (b) and Meso4 (c) cells were expressed as the percentage of proliferation relative to the
nontreated (control) cells as determined by the BrdU assay. Reductions on cell viability in hlMSC-CM-treated H28 (d), H2052 (e) and
Meso4 (f) cells were expressed as a percentage of cell viability relative to nontreated cells as evaluated by the XTT assay. Results are the
means ± standard deviations of three independent experiments each. **p < 0.01, ***p < 0.001, ****p < 0.0001. h Hours, hLMSC CM Human lung-derived
mesenchymal stem cell-conditioned media
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been demonstrated by the inhibition of tumor growth
in leukemia [24], prostate carcinoma [25], Kaposi’s
sarcoma [5], colon carcinoma [26], breast cancer [27]
and murine lung cancer [28] under in vitro and in vivo
conditions. Diverse mechanisms have been reported to
be involved in the antitumor potential of MSCs that in-
clude apoptosis caused by an upregulation of TRAIL,
cell cycle arrest, blocking of the PI3K/AkT pathway, ex-
pression of tumor suppressor genes, downregulation of
the Wnt pathway, expression of DKK1 and cytokine-
mediated process. Operationally, MSCs have also been
proven to home to tumor sites and exert suppression of
tumor growth amongst others [29]. Our data point to a
soluble factor-mediated antitumor effect of hlMSC-CM
reflecting the notion that hMSCs have the innate
capacity to produce biomolecules in response to the
tumor microenvironment.
Sphere formation represents one of the basic features
of CSCs, a rare subpopulation within a tumor, which is
supposed to be a crucial player in the initiation, invasive-
ness and drug tolerance in different tumors including
MPM [11, 30–35]. A striking property of hLMSC-CM
observed in this study is its capacity to fully eliminate
the sphere-forming phenotype in H28 cells. The failure
of hlMSC-CM to abolish the sphere-forming cells in
H2052 and Meso4 may be due to the differences in the
histological composition of the tested cell lines. MPM is
divided into three histological subtypes: epitheloid,
sarcomatoid and biphasic [9]. Multicellular spheroids
possess heterogeneity similar to that of tumor in vivo
Fig. 3 hlMSC-CM completely eliminates the sphere-forming cells in H28 cell line. Sphere-forming efficiencies of hlMSC-CM-treated cells were
determined and compared with those of the nontreated H28 (a), H2052 (b) and Meso4 (c) cells. Results represent the means ± standard
deviations of three experiments each. d-f Representative images of hlMSC-CM-treated and nontreated MPM cell lines as indicated. Images
were taken with Leica DMI 4000B at 5× magnification. ****p < 0.0001. h Hours, hlMSC-CM Human lung-derived mesenchymal stem
cell-conditioned media
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and their drug resilience has appeared to be analo-
gous to the natural resistance observed in patient
tumors [36]. Therefore, testing for sphere formation
after drug treatment would represent a reliable
method to evaluate chemoresistance, not only in vitro
but also in an in vivo setting. Considering this,
hlMSC-CM, which showed a high potency to elimin-
ate tumor spheres, may be used to resolve drug toler-
ance in the epitheliod type of MPM as represented by
the H28 cell line. Cisplatin is one of the standard compo-
nents in the treatment of MPM, which as yet results in in-
adequate patient therapy [8]. Because the efficacy of
hlMSC-CM to eliminate the sphere-forming cells in H28
is higher compared with twice the IC50 of cisplatin, it
stands to reason that combining hlMSC-CM with
conventional drugs may improve the current treat-
ment modalities in MPM.
Conclusion
Our study demonstrates that hlMSC-CM exerts in vitro
antitumor effects in three MPM cell lines via soluble
factors, which offers a potentially useful tool to augment
the standard therapy in MPM.
Fig. 4 hlMSC-CM shows higher efficacy than twice the IC50 of cisplatin in inhibiting the growth of tumor spheres in H28 cells. H28 cells were
treated in the absence or presence hlMSC-CM (a), 1× IC50 cisplatin (b) and 2× IC50 cisplatin (c) at the indicated periods after which sphere-
formation assays were performed. Results indicate the sphere efficiencies of the hlMSC-CM-and cisplatin-treated cells relative to the nontreated
controls. d-f Representative images of the hlMSC-CM-, cisplatin-treated cells and nontreated cells as indicated. Data represent the means and ±
standard deviations of three independent experiments each. *p < 0.05, ***p < 0.001, ****p < 0.0001. h Hours, hlMSC-CM Human lung-derived
mesenchymal stem cell-conditioned media, IC50 Half maximal inhibitory concentration
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